Literature DB >> 23007118

Role of GB virus C in HIV-1-infected and hepatitis C virus-infected hemophiliac children and adolescents.

Solveig Tenckhoff1, Thorsten Kaiser, Fritz Bredeek, Sharyne Donfield, Erika Menius, Alice Lail, Joachim Mössner, Eric S Daar, Hans L Tillmann.   

Abstract

BACKGROUND: GB Virus C (GBV-C) has been associated with a better prognosis of HIV-1 disease in adults. Little is known about prevalence and interaction between GBV-C, HIV-1, and/or hepatitis C virus (HCV) in hemophiliac children and adolescents.
METHODS: A well-characterized cohort of HIV-1-infected and HIV-1-uninfected hemophiliac children and adolescents followed in the Hemophilia Growth and Development Study (HGDS) were evaluated using quantitative reverse transcription polymerase chain reaction to detect GBV-C RNA in samples from baseline and last follow-up visit.
RESULTS: HIV-1-infected (n = 202) and HIV-1-uninfected (n = 119) patients had a low prevalence of GBV-C infection at baseline (0.9 and 0%), which increased at time of last follow-up visit to 25.2% and 26.3%, respectively. In addition, at the time of the follow-up GBV-C measurement, those GBV-C infected had been followed longer and had higher CD4(+) cell counts and lower HIV-1 viral loads than those GBV-C uninfected. These beneficial effects of GBV-C were no longer significant after controlling for CD4(+) cell count and HIV-1 RNA at baseline. HCV RNA clearance was more common amongst those who were not GBV-C infected than those who became GBV-C viremic.
CONCLUSIONS: This study confirms a positive association of GBV-C with milder course of HIV-1 infection. GBV-C infection was associated with a higher likelihood of persistent HCV infection.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23007118      PMCID: PMC3548052          DOI: 10.1097/qai.0b013e31826218e1.

Source DB:  PubMed          Journal:  J Acquir Immune Defic Syndr        ISSN: 1525-4135            Impact factor:   3.731


  48 in total

1.  Prevalence and route of transmission of infection with a novel DNA virus (TTV), hepatitis C virus, and hepatitis G virus in patients infected with HIV.

Authors:  F Puig-Basagoiti; M Cabana; M Guilera; M Giménez-Barcons; G Sirera; C Tural; B Clotet; J M Sánchez-Tapias; J Rodés; J C Saiz; M A Martínez
Journal:  J Acquir Immune Defic Syndr       Date:  2000-01-01       Impact factor: 3.731

2.  Hospital admission is a relevant source of hepatitis C virus acquisition in Spain.

Authors:  Eva Martínez-Bauer; Xavier Forns; Mercé Armelles; Ramon Planas; Ricard Solà; Mercé Vergara; Silvia Fàbregas; Roser Vega; Javier Salmerón; Moisés Diago; Jose María Sánchez-Tapias; Miquel Bruguera
Journal:  J Hepatol       Date:  2007-10-12       Impact factor: 25.083

3.  The prevalence of serum GB virus C/hepatitis G virus RNA and anti-E2 in Japanese children without a history of blood transfusion.

Authors:  F Mizutani; K Sugiyama; K Goto; T Ando; K Terabe; Y Wada
Journal:  Tohoku J Exp Med       Date:  2000-03       Impact factor: 1.848

4.  The natural history of hepatitis C virus infection: host, viral, and environmental factors.

Authors:  D L Thomas; J Astemborski; R M Rai; F A Anania; M Schaeffer; N Galai; K Nolt; K E Nelson; S A Strathdee; L Johnson; O Laeyendecker; J Boitnott; L E Wilson; D Vlahov
Journal:  JAMA       Date:  2000-07-26       Impact factor: 56.272

5.  Prevalence of hepatitis G virus RNA in a monocentric population of French haemophiliacs.

Authors:  V Gerolami; P Halfon; H Chambost; F Sicardi; I Thuret; R Planells; G Halimi; C Fossat; G Michel; G Cartouzou
Journal:  Br J Haematol       Date:  1997-10       Impact factor: 6.998

6.  GB virus C/Hepatitis G virus infection is frequent in American children and young adults.

Authors:  A Handa; R F Jubran; B Dickstein; A Boylan; N L Luban; N S Young; K E Brown
Journal:  Clin Infect Dis       Date:  2000-03       Impact factor: 9.079

7.  Risk factors and outcome among a large patient cohort with community-acquired acute hepatitis C in Italy.

Authors:  T Santantonio; E Medda; C Ferrari; P Fabris; G Cariti; M Massari; S Babudieri; M Toti; R Francavilla; F Ancarani; G Antonucci; G Scotto; V Di Marco; G Pastore; T Stroffolini
Journal:  Clin Infect Dis       Date:  2006-09-27       Impact factor: 9.079

8.  HIV entry inhibition by the envelope 2 glycoprotein of GB virus C.

Authors:  Susan Jung; Melanie Eichenmüller; Norbert Donhauser; Frank Neipel; Alfred M Engel; Georg Hess; Bernhard Fleckenstein; Heide Reil
Journal:  AIDS       Date:  2007-03-12       Impact factor: 4.177

9.  Molecular epidemiology of GB virus C/hepatitis G virus in Athens, Greece.

Authors:  C G Anastassopoulou; D Paraskevis; N C Tassopoulos; J Boletis; V A Sypsa; G Hess; A Hatzakis
Journal:  J Med Virol       Date:  2000-07       Impact factor: 2.327

10.  Enhanced and resumed GB virus C replication in HIV-1-infected individuals receiving HAART.

Authors:  Per Björkman; Leo Flamholc; Vilma Molnegren; Aline Marshall; Nuray Güner; Anders Widell
Journal:  AIDS       Date:  2007-07-31       Impact factor: 4.177

View more
  4 in total

1.  Prevalence and Clinical Impact of Human Pegivirus-1 Infection in HIV-1-Infected Individuals in Yunnan, China.

Authors:  Zhijiang Miao; Li Gao; Yindi Song; Ming Yang; Mi Zhang; Jincheng Lou; Yue Zhao; Xicheng Wang; Yue Feng; Xingqi Dong; Xueshan Xia
Journal:  Viruses       Date:  2017-02-15       Impact factor: 5.048

Review 2.  Review of human pegivirus: Prevalence, transmission, pathogenesis, and clinical implication.

Authors:  Yaqi Yu; Zhenzhou Wan; Jian-Hua Wang; Xianguang Yang; Chiyu Zhang
Journal:  Virulence       Date:  2022-12       Impact factor: 5.882

3.  Co-infections and transmission networks of HCV, HIV-1 and HPgV among people who inject drugs.

Authors:  Kim Tien Ng; Yutaka Takebe; Jack Bee Chook; Wei Zhen Chow; Kok Gan Chan; Haider Abdulrazzaq Abed Al-Darraji; Adeeba Kamarulzaman; Kok Keng Tee
Journal:  Sci Rep       Date:  2015-10-13       Impact factor: 4.379

4.  Human pegivirus (HPgV, GBV-C) RNA in volunteer blood donors from a public hemotherapy service in Northern Brazil.

Authors:  Aniel de Sarom Negrão Silva; Clayton Pereira Silva; Rafael Ribeiro Barata; Pedro Victor Reis da Silva; Patrícia Danin Jordão Monteiro; Letícia Lamarão; Rommel Mário Rodríguez Burbano; Márcio Roberto Teixeira Nunes; Patrícia Danielle Lima de Lima
Journal:  Virol J       Date:  2020-10-14       Impact factor: 4.099

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.